Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Myobloc Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedCignaPolicy IP0509

    Botulinum Toxins - Myobloc

    Customize your policy alerts

    Sign up for Cigna Policy IP0509 alerts

    Get alerted when Policy IP0509 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs benefit coverage and prior authorization for Myobloc (rimabotulinumtoxinB injection) administered under Cigna health benefit plans. Coverage is subject to the applicable benefit plan, covered diagnoses and codes, documented medical-necessity criteria, and dosing requirements.

    Policy Summary
    PayerCigna
    PolicyBotulinum Toxins - Myobloc
    Policy CodePolicy IP0509
    Change TypeModified
    Effective DateNov 15, 2026
    Last ReviewOct 8, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit patient-specific documentation showing that the applicable criteria and dosing requirements are met.
    SourceLink
    POLICY UPDATE CHANGES

    Cervical dystonia criteria and dosing requirements were revised.

    The upper-limb spasticity dosing limit was reduced.

    Noncovered uses are now explicitly limited to cosmetic use, while other uses remain subject to medical-necessity criteria and available evidence.

    Four CPT codes were removed from the coding information.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    RequiredUtilization management requirement
    3Covered indications
    CosmeticExcluded use
    1 yearApproval duration
    15,000 unitsMaximum upper-limb spasticity dose
    12 weeksMinimum dosing interval

    Coverage Criteria

    Initial Therapy Criteria — Cervical Dystonia

    Approve for 1 year when all of the following criteria are met:

    Cervical dystonia

    • Age: Patient is 18 years of age or older.>=18 years
    • Diagnosis: Patient has a diagnosis of cervical dystonia.

      Documentation required.

    • Clinical findings: Patient has sustained head torsion and/or tilt with limited range of motion in the neck.

      Documentation required.

    • Specialist involvement: Myobloc is prescribed by or in consultation with a pain medicine specialist, neurologist, or physical medicine and rehabilitation physician.

    Initial Therapy Criteria — Chronic Sialorrhea

    Approve for 1 year when the following criterion is met:

    Chronic sialorrhea: Patient is 18 years of age or older.>=18 years

    Initial Therapy Criteria — Upper-Limb Spasticity

    Approve for 1 year when the following criterion is met:

    Upper-limb spasticity: Patient is 18 years of age or older.>=18 years

    Cosmetic use is excluded from recommended benefit coverage for Myobloc.

    Coverage is not recommended for cosmetic use of Myobloc because cosmetic indications are excluded from a typical medical benefit. Examples include facial rhytides, frown lines, glabellar wrinkling, horizontal neck rhytides, mid- and lower-face or neck rejuvenation, platysmal bands, and periorbital rejuvenation.

    Myobloc use outside the covered indications, including cosmetic use, is considered not medically necessary when the applicable policy medical-necessity criteria are not met.

    Coding and Dose Information

    Considered Medically Necessary CPT CodesCPTCovered
    64611Chemodenervation of parotid and submandibular salivary glands, bilateral
    Considered Medically Necessary HCPCS CodesHCPCSCovered
    J0587Injection, rimabotulinumtoxinB, 100 units
    CPT Codes Removed in Revision HistoryCPT
    64616Removed from coding information
    64642Removed from coding information
    64643Removed from coding information
    64644Removed from coding information
    Cervical Dystonia Initial Dose
    IndicationCervical dystonia
    Initial doseNot to exceed 5,000 units
    Administration frequencyNot more frequently than once every 12 weeks
    Cervical Dystonia Maximum Dose
    IndicationCervical dystonia
    Maximum doseUp to 10,000 units
    Initial-dose limit

    Provider and Authorization Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of Myobloc (rimabotulinumtoxinB).

    Prior Authorization

    Approval Depends on Policy Criteria and Dosing

    Approval is recommended only when the applicable indication criteria and policy dosing requirements are met. Requests for doses outside the established dosing are reviewed case by case by a clinician.

    Documentation Required

    Submit Patient-Specific Supporting Documentation

    Submit patient-specific supporting documentation with each authorization request. Acceptable records may include chart notes, laboratory tests, medical test results, claims records, and other relevant information; all documentation must include patient-specific identifying information.

    Clinical Background

    Myobloc (rimabotulinumtoxinB) is an acetylcholine-release inhibitor and neuromuscular-blocking agent. The policy addresses its use in adults with cervical dystonia and chronic sialorrhea; adult upper-limb spasticity is also addressed based on supportive evidence. Botulinum toxin products carry a boxed warning regarding possible distant spread of toxin effect, including serious swallowing and breathing difficulties.

    Definitions

    Botulinum Toxin Potency Units
    Product specificityPotency units are specific to each botulinum toxin product
    InterchangeabilityUnits are not interchangeable with units of another botulinum toxin product
    ConversionUnits are not directly convertible to units of another botulinum toxin product
    Cervical Dystonia
    ConditionCervical dystonia
    Alternate termSpasmodic torticollis
    Policy contextListed as an FDA-approved indication for adults

    Initial Therapy Criteria

    Cervical Dystonia — Initial Therapy

    Approve for 1 year when all of the following criteria are met:

    Cervical dystonia

    • Age: Patient is 18 years of age or older.>=18 years
    • Diagnosis: Patient has a diagnosis of cervical dystonia.

      Documentation required.

    • Clinical findings: Patient has sustained head torsion and/or tilt with limited range of motion in the neck.

      Documentation required.

    Quantity Limits

    Myobloc — Cervical Dystonia
    DrugMyobloc
    Cervical dystonia quantity limitUp to 10,000 units per administration
    Initial doseNot to exceed 5,000 units
    Myobloc — Chronic Sialorrhea
    DrugMyobloc
    Chronic sialorrhea quantity limitUp to 3,500 units per administration
    Per-side limit1,750 units per side
    Policy Summary
    PayerCigna
    PolicyBotulinum Toxins - Myobloc
    Policy CodePolicy IP0509
    Change TypeModified
    Effective DateNov 15, 2026
    Last ReviewOct 8, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit patient-specific documentation showing that the applicable criteria and dosing requirements are met.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Dose InformationProvider and Authorization ActionsClinical BackgroundDefinitionsInitial Therapy CriteriaQuantity Limits
    Initial dose not to exceed 5,000 units
    Dosing Interval
    Dosing intervalNot more frequently than once every 12 weeks
    Applies toCervical dystonia, chronic sialorrhea, and upper-limb spasticity
    Administration basisPer administration
    Chronic Sialorrhea Maximum Dose
    IndicationChronic sialorrhea
    Maximum doseUp to 3,500 units
    Per-side limit1,750 units per side
    Upper-Limb Spasticity Maximum Dose
    IndicationUpper-limb spasticity
    Maximum doseUp to 15,000 units
    Administration frequencyNot more frequently than once every 12 weeks
    • Chart notes
    • Laboratory tests
    • Medical test results
    • Claims records
    • Other relevant patient-specific information
    Documentation Required

    Required Clinical Documentation

    Provide documentation wherever the criteria identify a requirement as [documentation required], including the applicable diagnosis and clinical findings.

    • Documentation is required for the cervical dystonia diagnosis.
    • Documentation is required for sustained head torsion and/or tilt with limited neck range of motion.

    Unsupported block type: documentation

    Denial Risk

    Uncovered Diagnosis or Code

    Reimbursement may be denied when services are billed for conditions or diagnoses not covered by the policy or when the claim lacks applicable covered diagnosis or procedure codes. Use the most appropriate codes in effect on the submission date.

    • Claims submitted without covered code(s) may be denied as not covered.
    • Unsupported or noncovered diagnoses and coding are not reimbursable.
    Denial Risk

    Cosmetic Use Not Covered

    Benefit coverage is not recommended for cosmetic use, including facial rhytides, frown lines, glabellar wrinkling, horizontal neck rhytides, facial or neck rejuvenation, platysmal bands, or periorbital rejuvenation.

    Denial Risk

    Failure to Meet Authorization Criteria

    Requests may be denied when prior authorization is not obtained, policy criteria or medical necessity are not met, dosing exceeds policy limits or frequency requirements, or the requested use is excluded. Myobloc for uses other than covered indications is considered not medically necessary.

    • Cervical dystonia: maximum 10,000 units; initial dose must not exceed 5,000 units; no more frequently than every 12 weeks.
    • Chronic sialorrhea: maximum 3,500 units, with 1,750 units per side; no more frequently than every 12 weeks.
    • Upper-limb spasticity: maximum 15,000 units; no more frequently than every 12 weeks.
    • Cosmetic use and other noncovered uses may be denied.
    Specialist involvement: Myobloc is prescribed by or in consultation with a pain medicine specialist, neurologist, or physical medicine and rehabilitation physician.

    Chronic Sialorrhea — Initial Therapy

    Approve for 1 year when the following criterion is met:

    Chronic sialorrhea: Patient is 18 years of age or older.>=18 years

    Upper-Limb Spasticity — Initial Therapy

    Approve for 1 year when the following criterion is met:

    Upper-limb spasticity: Patient is 18 years of age or older.>=18 years
    Myobloc — Upper-Limb Spasticity
    DrugMyobloc
    Upper-limb spasticity quantity limitUp to 15,000 units per administration
    Dosing intervalNot more frequently than once every 12 weeks
    Myobloc — Dosing Interval
    DrugMyobloc
    Dosing intervalNot more frequently than once every 12 weeks
    Covered indicationsCervical dystonia, chronic sialorrhea, and upper-limb spasticity